Low-dose CT screening reduces lung cancer mortality and improves survival in broad populations

Cracking the code: Bispecific immunotherapy in small cell lung cancer

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC

Durvalumab after SBRT reduces tumour progression in early-stage NSCLC

Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer

Reducing cancer burden through prevention

Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform

Tepotinib in second line NSCLC treatment

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC